[
  {
    "objectID": "Training.html",
    "href": "Training.html",
    "title": "Teaching and Training",
    "section": "",
    "text": "JTK"
  },
  {
    "objectID": "Training.html#graduate-student-instructor",
    "href": "Training.html#graduate-student-instructor",
    "title": "Teaching and Training",
    "section": "Graduate Student Instructor",
    "text": "Graduate Student Instructor\nWestern Michigan University, Department of Statistics\nAug 2023 ‚Äì Apr 2025\n\nSTAT 1600 ‚Äì Discovery With Data\n\n\n\n\n\nDepartment of Statistics\nInstructor\nSpring & Fall 2023-2025\nServed as Graduate Student instructor and provided lab sessions in undergraduate statistics; covering descriptive stats, hypothesis testing, and simple regression.\n\n\n\n\n\nSTAT 2160 ‚Äì Business Statistics\n\n\n\n\n\nDepartment of Statistics\nTutor\nFall 2023, Spring 2024 Led weekly labs and grading for undergraduate business statistics, covering descriptive stats, hypothesis testing, and regression.\n\n\n\n\n\nSTAT STAT 3620 ‚Äì Probability\n\n\n\n\n\nDepartment of Statistics\nTutor\n(Fall 2023, Fall 2024 Delivered lab sessions and tutorials on combinatorics, discrete/continuous distributions, and probability theory.\n\n\n\n\n\nSTAT 2600 ‚Äì R Statistical Programming and Computing\n\n\n\n\n\nDepartment of Statistics\nTutor\nSpring 2024,2025 Provided lab sessions in R programming for undergraduate students."
  },
  {
    "objectID": "Training.html#research-teaching-assistant",
    "href": "Training.html#research-teaching-assistant",
    "title": "Teaching and Training",
    "section": "Research & Teaching Assistant",
    "text": "Research & Teaching Assistant\nUniversity of Ghana, Department of Statistics & Actuarial Science\nAug 2018 ‚Äì Aug 2023\n\n\nSTAT 111 ‚Äì Introduction to Statistics\n\n\n\n\n\nDepartment of Statistics & Actuarial Science\nInstructor\n(2022‚Äì2023) Conducted tutorials and assessments for introductory topics in descriptive and inferential statistics.\n\n\n\n\n\nSTAT 221 ‚Äì Intro. to Statistical And Probability I\n\n\n\n\n\nDepartment of Statistics & Actuarial Science\nInstructor/ TA\n(2023) Aided in teaching probability foundations, moment-generating functions, and common distributions\n\n\n\n\n\nSTAT 333 ‚Äì Statistical Inference\n\n\n\n\n\nDepartment of Statistics & Actuarial Science\nTutor\n(2023) Supported instruction as a TA in hypothesis testing, sampling distributions, and interval estimation.\n\n\n\n\n\nACTU 605- Actuarial Mathematics\n\n\n\n\n\nDepartment of Statistics & Actuarial Science\nTA\n(2022-2023) Provided teaching assistant duties in life contingencies, survival models, and premium calculation principles for Mphil students.\n\n\n\n\n\nACTU 405- Actuarial Economics\n\n\n\n\n\nDepartment of Statistics & Actuarial Science\nInstructor/ TA\n(2022-2023) Served as both instructor and TA for topics blending economic principles with actuarial valuation and risk theory.\n\n\n\n\n\nACTU 345- Actuarial Statistics\n\n\n\n\n\nDepartment of Statistics & Actuarial Science\nTA\n(2023) Provided teaching assistant duties in interests rates, Annuities, Bonds, and premium calculation principles to Undergraduates students.\n\n\n\n\n\nStatistics and Actuarial Consulting Unit (SACU)\n\n\n\n\n\nDepartment of Statistics & Actuarial Science\nResearch Assistant\n(2022-2023) Collaborated with faculty on research in reserach activities and statistical and actuarial consulting."
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "Awards & Honors",
    "section": "",
    "text": "My motivation stems from a deep conviction that statistical thinking can transform how we understand disease, deliver treatment, and personalize care. My ultimate focus is the intersection of Bayesian statistcis, clinical trials, causal inference, precision medicine, survival modeling, Hidden Markov Chains, machine (deep) learning , where data-driven findings and the power of novel statistical methods can directly inform therapeutic development. My commitment to advancing evidence-based public health through rigorous statistical modeling and innovation drives both my academic research and professional ambitions."
  },
  {
    "objectID": "about.html#section",
    "href": "about.html#section",
    "title": "Awards & Honors",
    "section": "2025",
    "text": "2025\n\nArnold School Dean‚Äôs Research Travel Award, Arnold School of Public Health, University of South Carolina (2025)\nPharmaSUG 2025 Conference Travel Grant ‚Äì Western Michigan University\nAwarded a conference travel grant of $1,000 to attend PharmaSUG 2025 in San Diego, recognizing excellence in clinical research and statistical programming.\nPharmaSUG 2025 Student Scholarship ‚Äì June 2025. Recipient of a competitive award recognizing outstanding potential in clinical research and statistical programming across the entire US."
  },
  {
    "objectID": "about.html#section-1",
    "href": "about.html#section-1",
    "title": "Awards & Honors",
    "section": "2024",
    "text": "2024\n\nGerald Sievers Memorial Scholarship ‚Äì May 2024. $2,000 merit-based scholarship awarded to the most outstanding statistics graduate student at Western Michigan University.\nASA Diversity Mentoring Program Scholar ‚Äì 2024. Selected for a national program supporting underrepresented students in statistics through mentorship and career development. $800."
  },
  {
    "objectID": "about.html#section-2",
    "href": "about.html#section-2",
    "title": "Awards & Honors",
    "section": "2023",
    "text": "2023\n\nBest Teaching Assistant Award, University of Ghana ‚Äì June 2023. Honored by the School of Mathematical Sciences for exceptional commitment to undergraduate instruction and mentoring. Selected as top-performing TA out of 20+ departmental TAs"
  },
  {
    "objectID": "about.html#section-3",
    "href": "about.html#section-3",
    "title": "Awards & Honors",
    "section": "2022",
    "text": "2022\n\nCertification of Honor\nUniversity of Ghana Actuarial and Statistics Society ‚Äî Honored for tremendous service and commitment through 2 years of effective transformative leadership as Deputy Project and Program Head."
  },
  {
    "objectID": "about.html#section-4",
    "href": "about.html#section-4",
    "title": "Awards & Honors",
    "section": "2018",
    "text": "2018\n\nGhana National Petroleum Corporation STEM Scholarship Recipient ‚Äì 2018‚Äì2022. Fully funded four-year national scholarship awarded to top STEM students in Ghana. First year: Gh9,000 and Gh7000 for the remaining 3-years."
  },
  {
    "objectID": "about.html#section-5",
    "href": "about.html#section-5",
    "title": "Awards & Honors",
    "section": "2017",
    "text": "2017\n\nBest Economics Student, WASSCE 2017 ‚Äì ADA Senior H.T School. Graduated with distinction in Economics, recognized as the highest-performing student in the subject across the school cohort."
  },
  {
    "objectID": "about.html#section-6",
    "href": "about.html#section-6",
    "title": "Awards & Honors",
    "section": "2015",
    "text": "2015\n\nLess Endowed Scholar 2015- 2017, ‚Äì ADA Senior H.T School. A tuition scholarship awarded to the top 3 students in each department school-wide. Recognized among the top 3 in the Business Department."
  },
  {
    "objectID": "about.html#volunteer",
    "href": "about.html#volunteer",
    "title": "Awards & Honors",
    "section": "Volunteer",
    "text": "Volunteer\n\nVolunteer Judge, PharmaSUG 2025 ‚Äì Feb 2025. Reviewed statistical research presentations for clarity, rigor, and innovation in clinical trial applications.\nPlanning Committee Member, ASA StatFest ‚Äì 2023‚ÄìPresent. Helped organize national outreach events promoting statistics among underrepresented communities.\nAcademic Integrity Committee Representative Western Michigan University-2024-2025 Promoted academic integrity by reviewing cases and setting standards for student across the University\nEmergency Team Leader- International Student Week Celebration, Western Michigan University-Oct 2023 Led emergency response planning to ensure event safety"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Josh T‚ÄôK, Gstat",
    "section": "",
    "text": "LinkedIn\n  \n  \n    \n     ResearchGate\n  \n  \n    \n     Github\n  \n  \n    \n     Rpubs\n  \n  \n    \n     Email\n  \n\n  \n  \n\n\n\nJTK‚Äôs Webpage\n\n\n\n\nMy research lies at the interface of statistics and science, with a particular focus on the development of Bayesian, survival, and causal methodologies for the analysis of complex dynamical Time series, Precision Medicine, Clinical Trial Design, Neuroscience, and Genomics.\n\n\n\nBeyond research and statistics, I enjoy:\n\nReading scientific literature and Programming üìàüíª\nWatching aircraft documentaries and aviation technology features üõ©Ô∏è\nA little bit drumming & cooking üòé\n\nListening to music to unwind üé∂\nAcademic discussions & debates üíª"
  },
  {
    "objectID": "index.html#experience",
    "href": "index.html#experience",
    "title": "Josh T‚ÄôK, Gstat",
    "section": "Experience",
    "text": "Experience\nResearch Assitant~ USC\n\nBayesian methodologies ‚Ä¢ Hidden Markov Models ‚Ä¢ Graphical Models ‚Ä¢ Dynamical time series ‚Ä¢ Neuroscience ‚Ä¢ Variable Selection\n\nAdvisor: Dr.¬†Beniamino H\nGraduate Student Instructor~ WMU\nEx-Intern, Masters Statistician~ Eli Lilly & Company\nTeaching & Research Assistant~ UG"
  },
  {
    "objectID": "index.html#education",
    "href": "index.html#education",
    "title": "Josh T‚ÄôK, Gstat",
    "section": "Education",
    "text": "Education\nPhD in Biostatistics | Aug 2025 ‚Äì Present ~ USC\nNon-Degree in Biostatistics | Summer 2025 ~ UCONN\nMS in Statistics & Certificate in Biostatistics| Aug 2023 ‚Äì April 2025 ~ WMU\nBSC in Mathematical (Actuarial) Sciences | Aug 2018 ‚Äì Nov 2022~ UG"
  },
  {
    "objectID": "index.html#about-me",
    "href": "index.html#about-me",
    "title": "Josh T‚ÄôK, Gstat",
    "section": "About Me",
    "text": "About Me\nHello! I‚Äôm Josh Korley, a motivated and research-driven doctoral student in Biotatistics at Arnold School Of Public Health, USC with a strong foundation in statistics, data and actuarial sciences."
  },
  {
    "objectID": "Projects.html",
    "href": "Projects.html",
    "title": "Projects",
    "section": "",
    "text": "Covariate-Adjusted Treatment Effects for Recurrent Events with Terminal Outcomes\n\nCovariate-Adjusted Treatment Effects for Recurrent Events with Terminal Outcomes\nAffiliation: Arnold School of Public Health | Oct 2025 ‚Äì Present\nKeywords: Recurrent events; terminal events; causal inference; covariate adjustment; clinical trials; survival analysis\n\nFoundational work:\nSun, J., Ye, T., et al.\nImprove the Precision of Area Under Curve Estimation for Recurrent Events Through Covariate Adjustment\nhttps://arxiv.org/html/2410.24163v3\n\n\n\nTo develop an estimand-driven, covariate-adjusted causal framework for treatment effects on recurrent clinical outcomes when a terminal event (e.g., death) may change survival and, as a consequence, the amount of time recurrent outcomes are observable. \n\n\n\nRecurrent event endpoints are common in clinical trials, including adverse events, hospitalizations, and disease flares. When a terminal event occurs, standard summaries of recurrent outcomes can be difficult to interpret because treatment can affect both (i) the recurrence process and (ii) survival time.\nRecent work by Sun and Ye et al. developed covariate-adjusted inference for an AUC of the mean cumulative function (MCF) estimand. Their estimand can be written (schematically) as an AUC functional of an MCF that depends on both the recurrent event rate and survival. As a result, when treatment affects survival, the estimand can change even if the underlying recurrent event rate does not, complicating scientific interpretation in settings where the goal is to isolate recurrence effects. \n\n\n\nThis project extends the Sun‚ÄìCook line of work by refining the causal estimand and developing an estimator that targets recurrence effects in a way that is orthogonal to survival differences. The goal is an estimand whose treatment contrast is zero when treatment affects survival only (but not recurrence), and nonzero only when treatment changes recurrence dynamics.\nKey contributions: - A survival-orthogonal recurrence-burden estimand that removes survival-weighting from the target, improving interpretability when survival differs by arm. - An orthogonal, influence-function‚Äìbased estimator enabling: - valid covariate-adjusted inference,\n- robustness to nuisance-model misspecification,\n- improved precision under randomized trials. - A causal framing aligned with modern estimand principles for intercurrent events in clinical trials. \n\n\n\nSimulations were conducted under three mechanisms:\n\nNo treatment effect on survival\n\nTreatment benefit on survival\n\nTreatment harm on survival\n\nAcross scenarios, we compared:\n\nthe proposed orthogonal estimator, and\n\nestimators corresponding to standard MCF/AUC-based summaries from prior literature.\n\nPerformance metrics included bias, variance, and power under covariate adjustment. \n\n\n\nLet \\(N_i(t)\\) denote the counting process for recurrent events up to time \\(t\\) for subject \\(i\\), and let \\(D_i\\) denote the terminal event time (e.g., death). Let \\(C_i\\) denote administrative censoring and \\(T_i=\\min(D_i,C_i)\\), with at-risk indicator \\(Y_i(t)=I(T_i\\ge t)\\). Let \\(A_i\\in\\{0,1\\}\\) denote treatment assignment.\nA common summary for recurrent events is the mean cumulative function (MCF): \\[\n\\mu_a(t)=\\mathbb{E}\\{N_i(t)\\mid A_i=a\\},\n\\] which averages recurrent event counts over all individuals. In the presence of a terminal event, MCF-based AUC summaries typically incorporate survival, so treatment effects on survival can influence the estimand even when recurrence dynamics are unchanged.\n\n\nDefine the marginal cumulative recurrence rate (Nelson‚ÄìAalen type target) \\[\nR_a(t)=\\int_0^t \\mathbb{E}\\{\\lambda_a(u\\mid X)\\}\\,du,\n\\] where \\(\\lambda_a(u\\mid X)\\) is the recurrent event intensity among those at risk under treatment \\(a\\).\nWe define the orthogonal recurrence-burden AUC \\[\n\\widetilde U_a(\\tau)=\\int_0^\\tau R_a(t)\\,dt\n=\\int_0^\\tau (\\tau-u)\\,dR_a(u),\n\\] and the treatment contrast \\[\n\\Delta_{\\text{orth}}(\\tau)=\\log\\left\\{\\frac{\\widetilde U_1(\\tau)}{\\widetilde U_0(\\tau)}\\right\\}.\n\\]\nKey property (survival orthogonality): if \\(dR_1(u)=dR_0(u)\\) for all \\(u\\le\\tau\\), then \\(\\widetilde U_1(\\tau)=\\widetilde U_0(\\tau)\\) and \\(\\Delta_{\\text{orth}}(\\tau)=0\\), even when survival differs by arm. This isolates recurrence effects from survival effects and yields a clearer clinical interpretation. \n\n\n\n\n\n\nThe orthogonal estimator closely tracks the true recurrence effect across regimes, while standard AUC-based estimators deviate when survival differs by treatment arm.\n \n##### Bias Induced by Survival Effects\nWhen survival is treatment-dependent, MCF/AUC-based estimators can exhibit systematic bias relative to a pure recurrence target. The orthogonal estimand substantially reduces this bias.\n \n\n\n\nAfter covariate adjustment, the orthogonal estimator maintains competitive or improved power without inflating type I error.\n \n\n\n\n\nThis framework supports clearer interpretation of repeated clinical outcomes in the presence of death or permanent discontinuation, with direct relevance to: - safety endpoints,\n- recurrent hospitalizations,\n- chronic disease flares,\n- oncology and neurodegenerative trials. \n\n\n\n\nMethodological development complete\n\nSimulation study ongoing\n\nManuscript in preparation"
  },
  {
    "objectID": "Projects.html#survival-causal-inference-analysis",
    "href": "Projects.html#survival-causal-inference-analysis",
    "title": "Projects",
    "section": "Survival & Causal Inference Analysis",
    "text": "Survival & Causal Inference Analysis\n\nIndividualized Treatment Effects in Advanced Prostate Cancer: A Causal-Survival Modeling Approach to Risk-Guided Therapy\n Individualized Treatment Effects in Advanced Prostate Cancer: A Causal-Survival Modeling Approach to Risk-Guided Therapy\nAffiliation: Western Michigan University | April 2025 ‚Äì Present\n\nDataset\nRandomized trial of 475 men treated with high- vs.¬†low-dose diethylstilbestrol (DES) for advanced prostate cancer\n\n\nObjective\nTo evaluate treatment effect heterogeneity and guide individualized therapy decisions using risk-adaptive modeling\n\n\nMethods\nSemi-parametric Cox proportional hazards models with treatment‚Äìcovariate interactions\nCausal inference via potential outcomes framework to estimate individualized treatment effects (ITEs)\nContinuous effect modification analysis using tumor size and patient age Delta Method to estimate the variance of ITE to enable confidence interval construction.\n\n\nResult\nHigh-dose DES was not beneficial on average (HR = 0.851; p = 0.519) Significant effect modification: patients with large tumors benefited (interaction HR = 0.691; p = 0.005), while patients over 70 faced increased risk (interaction HR = 1.064; p &lt; 0.001)\nVisualizations of patient-specific hazard ratios supported precision treatment strategies which existing studies could not address.\n\n\n\n\nHeart Failure Survival Analysis Using Machine Learning and Causal Methods Methods\n Heart Failure Survival Analysis Using Machine Learning and Causal Inference Methods\nAffiliation: Western Michigan University | Oct 2024 ‚Äì Dec 2024\n\nDataset\nClinical records from 299 heart failure patients (Faisalabad Institute of Cardiology & Allied Hospital, Pakistan)\n\n\nObjective\nTo identify key predictors of survival in heart failure patients and explore clinical mediation pathways.\n\n\nMethods\nSupervised learning: Logistic Regression, Random Forest, Support Vector Machine (SVM)\nPenalized regression: LASSO, Ridge, Elastic Net\nStructural Equation Modeling (SEM) for mediation analysis of prognostic variables\n\n\nResult\nEjection fraction, serum sodium, and serum creatinine were consistently identified as the strongest survival predictors. Models achieved high AUC and specificity, with interpretable results supporting data-informed clinical decision-making."
  },
  {
    "objectID": "Projects.html#numerical-method-based-estimation",
    "href": "Projects.html#numerical-method-based-estimation",
    "title": "Projects",
    "section": "Numerical Method Based Estimation",
    "text": "Numerical Method Based Estimation\n\nCensored Survival Time Estimation Using EM Algorithm\n Censored Survival Time Estimation Using EM Algorithm\nAffiliation: Dept. of Statistics, Western Michigan University | Aug 2024 ‚Äì Present\nDataset: Motorette lifespan data (Schnee & Hahn, 1979)\nPurpose: To explore statistical modeling strategies for analyzing censored time-to-event data\nMethods:\n- Leveraged the power of Expectation‚ÄìMaximization (EM) algorithm to estimate patients‚Äô interval censored survival time. - Kaplan‚ÄìMeier and parametric survival modeling (visuals)\nResult: EM algorithm demonstrated strong performance in recovering latent survival distribution under random censoring. Insights were applied to inform experimental design strategies in clinical trials."
  },
  {
    "objectID": "Projects.html#clinical-trial--epibiostatistics",
    "href": "Projects.html#clinical-trial--epibiostatistics",
    "title": "Projects",
    "section": "Clinical Trial- Epi/Biostatistics",
    "text": "Clinical Trial- Epi/Biostatistics\n\nClinical Epidemiology Project: Alzheimer‚Äôs Disease Subgroup Analysis\n Clinical Epidemiology Project: Alzheimer‚Äôs Disease Subgroup Analysis \nAffiliation: Summer Research, Western Michigan University | Jun 2024 ‚Äì Aug 2024\nDataset: ACTC Solanezumab Preclinical Trial Data\nPurpose: To assess subgroup-specific treatment effects and identify cognitive decline risk factors\nMethods:\n- Regression modeling on MMSE and ARIA endpoints\n- Subgroup analyses by APOE4 status, centiloid level, education, and BMI\nResult: Found that surrogate endpoint selection (MMSE vs.¬†ARIA) influences identified risk profiles. APOE4 status and centiloid level showed consistent association with AD progression across subgroups."
  },
  {
    "objectID": "Projects.html#health-epidemiology",
    "href": "Projects.html#health-epidemiology",
    "title": "Projects",
    "section": "Health & Epidemiology",
    "text": "Health & Epidemiology\n\n\nForecasting Lung Cancer Mortality\nCompared time series models (SES, HDES, ARIMA) for lung cancer prediction in the U.S."
  },
  {
    "objectID": "Projects.html#never-ending-analysis",
    "href": "Projects.html#never-ending-analysis",
    "title": "Projects",
    "section": "Never Ending-Analysis",
    "text": "Never Ending-Analysis\n\n1.HIV: MIxed-Models- Pending\n Evaluating the Effectiveness of HAART Regimens on CD4 Cell Count Trajectories in HIV-Infected Women\nAffiliation: Final Project, Western Michigan University | Jan 2024 ‚Äì Apr 2024\n\nDataset\nWomen‚Äôs Interagency HIV Study (WIHS), 274 HIV-positive women observed over 9 visits across 54 months\n\n\nPurpose\nTo assess the impact of HAART regimen type on immune restoration (CD4 cell count) and investigate subgroup-specific treatment responses\n\n\nMethods\n\nRegression modeling on log-transformed CD4 counts at last visit using OLS\n\nLongitudinal analysis using GLS and linear mixed-effects models\n\nSubgroup effect estimation using interaction terms (age, IDU, alcohol, smoking)\n\n\n\nResults\nMonotherapy and Triple therapy were associated with higher CD4 restoration than Dual therapy, especially among women with injection drug use. The interaction effects revealed that treatment effectiveness varied significantly across subgroups, notably IDU and smoking status. CD4 improvement trajectories declined over time for all regimens, with Monotherapy and Triple therapy showing slower decline rates. These findings emphasize the importance of personalized HAART strategies based on behavioral and clinical profiles.\n\n\n\n\n2. Methodological Comparison of Longitudinal Models for HAART Data: Addressing Small Sample Sizes and Unbalanced Designs -Pending\n Methodological Comparison of Longitudinal Models for HAART Data: Addressing Small Sample Sizes and Unbalaned Designs \nAffiliation: Final Project, Western Michigan University | Jan 2024 ‚Äì Apr 2024\n\nDataset\nSimulated and real data from the WIHS cohort (274 HIV-positive women followed over 54 months with CD4 counts recorded at 9 visits)\n\n\nPurpose\nTo compare the performance of LME, GEE, and GLMM in estimating HAART treatment effects under small sample sizes and unbalanced longitudinal designs\n\n\nMethods\n\nApplied LME, GEE, and GLMM to subsets of longitudinal data\n\nEvaluated statistical power, estimation accuracy, and computational efficiency\n\nModeled interaction effects (e.g., treatment √ó time, treatment √ó IDU, treatment √ó smoking) across simulated sample sizes (n = 10, 20, 50, 100, 200)\n\n\n\nResult\nGLMM demonstrated superior accuracy and robustness across varying sample sizes, especially with non-normal outcomes. LME and GEE yielded comparable estimates at larger sample sizes, but diverged under smaller or unbalanced conditions. Interaction terms such as HAART √ó IDU and HAART √ó smoking status significantly influenced CD4 trajectories. Results guide model choice in HIV studies based on data characteristics, with GLMM preferred when flexibility and subject-level effects are key.\n\n\n\n\nSAS-Based Risk Modeling\nAffiliation: Volunteer Research Assistant, Western Michigan University | Aug 2024 ‚Äì Present\n\nDataset\nClinical trial and epidemiological datasets on lung cancer and age-related illness\n\n\nPurpose\nTo explore risk factor modeling and the effect of censoring in survival studies\n\n\nMethods\n\nSurvival analysis using SAS\n\nCox models and regression diagnostics\n\n\n\nResult\nSupported methodological development for censoring-adjusted survival estimation. Assisted in validating models on age-related disease outcomes."
  },
  {
    "objectID": "Publications.html",
    "href": "Publications.html",
    "title": "Publications & Conferences",
    "section": "",
    "text": "1.Kubuafor, E., Korley, J.T._, et al.¬†(2024). Evaluation of Time Series Forecasting Models for Predicting Lung Cancer Mortality Rates in the United States: A Comparison with Altuhaifa (2023) Study.Proceedings of the Mediterranean Life Sciences Union Annual Meeting (MEDLIFE-24), Istanbul, Turkey, 08-10 December 2024. Springer Proceedings in Mathematics & Statistics* (In Press.)"
  },
  {
    "objectID": "Publications.html#manuscript-under-review",
    "href": "Publications.html#manuscript-under-review",
    "title": "Publications & Conferences",
    "section": "",
    "text": "1.Kubuafor, E., Korley, J.T._, et al.¬†(2024). Evaluation of Time Series Forecasting Models for Predicting Lung Cancer Mortality Rates in the United States: A Comparison with Altuhaifa (2023) Study.Proceedings of the Mediterranean Life Sciences Union Annual Meeting (MEDLIFE-24), Istanbul, Turkey, 08-10 December 2024. Springer Proceedings in Mathematics & Statistics* (In Press.)"
  },
  {
    "objectID": "Publications.html#manuscripts-in-preparation",
    "href": "Publications.html#manuscripts-in-preparation",
    "title": "Publications & Conferences",
    "section": "Manuscripts In Preparation",
    "text": "Manuscripts In Preparation\n1.Korley, J.T.* (2025). Covariate-Adjusted Treatment Effects for Recurrent Events with Terminal Outcomes  2.Korley, J.T.* (2025). Timing of First Neuroimaging in Alzheimer‚Äôs Disease: A Competing-Risk Analysis of Genetic, Cognitive,& Demographic Determinants  3. Korley, J.T.* & Adu Bonsu, E. (2025). Bayesian Hierarchical Modeling of Time-to-Dropout in Alzheimer‚Äôs Disease Research Cohorts.  4.Korley, J.T.* (2025). Robust Survival Estimation under Interval Censoring: Expectation-Maximization and Bayesian Accelerated Failure Time Assessment via Simulation and Application.  5.Korley, J.T.* (2025). Individualized Treatment Effects in Advanced Prostate Cancer: A Survival Modeling Approach to Risk-Guided Therapy."
  },
  {
    "objectID": "Publications.html#new-project--framework",
    "href": "Publications.html#new-project--framework",
    "title": "Publications & Conferences",
    "section": "New Project- Framework",
    "text": "New Project- Framework\nHigh-Dimensional Mediation Analysis with Survival Outcomes: A Double Machine Learning and Causal Inference Approach.\n- Development of JsurvMediateML, an R package for implementing high-dimensional survival mediation analysis with clinical applications."
  },
  {
    "objectID": "Updates.html",
    "href": "Updates.html",
    "title": "Update and Events",
    "section": "",
    "text": "NACC- September, 2025- Present  Timing of First Neuroimaging in Alzheimer‚Äôs Disease: A Competing-Risk Analysis of Genetic, Cognitive,& Demographic Determinants ~ Current Research \nNACC- July, 2025- Present Bayesian Hierarchical Modeling of Time-to-Dropout in Alzheimer‚Äôs Disease Research Cohorts. ~ Current Research \nJune 2nd, 2025\n\n\n\n\nHonored by the PharmaSUG Conference Committee with a Scholarship Award and Certificate of Achievement for my commitment to advancing clinical research and data science.\n\n\n\nJune 1st - 4th, 2025  \nOld Events In Archive\n\nChill~ Move"
  },
  {
    "objectID": "Projects.html#clinical-trials",
    "href": "Projects.html#clinical-trials",
    "title": "Projects",
    "section": "Clinical Trials",
    "text": "Clinical Trials\n\nBiopharmaceutical Research Project: Dose-Finding and Missing Data Analysis in Psoriasis Trial\n\nBiopharmaceutical Research Project: Dose-Finding and Missing Data Analysis in Psoriasis Trial\nAffiliation: Biopharmaceutical Summer Academy, University of Connecticut | Jul 2025 ‚Äì Aug 2025\n\nDataset\nSimulated Phase II Trial Data for Brodalumab (Psoriasis Therapy)\n\n\nPurpose\nTo determine optimal dosing and evaluate the robustness of early efficacy signals under clinically realistic dropout scenarios\n\n\nMethods\n\nBridge-penalized logistic regression modeling on PASI75 (primary) and PASI50 (validation) endpoints\n\nSimulated missingness mechanisms: MCAR, MAR (response-based), MNAR (toxicity-index based)\n\nMultiplicity control and decision reliability assessment across sample sizes\n\nSensitivity analyses via complete-case analysis, non-responder imputation, and full-data logistic regression\n\n\n\nResult\nAcross all modeling strategies, the 140 mg and 210 mg doses consistently demonstrated superior clinical efficacy. Despite convergence issues with sparse placebo response under PASI75, results were validated via PASI50 with placebo as reference. The bridge penalization approach improved estimation stability by borrowing strength from an anchor dose while maintaining flexibility. Findings support the advancement of 140 mg and 210 mg doses for Phase III trials. Simulated dropout patterns mirror real-world early-phase attrition, enhancing decision utility."
  },
  {
    "objectID": "Projects.html#epibiostatistics",
    "href": "Projects.html#epibiostatistics",
    "title": "Projects",
    "section": "Epi/Biostatistics",
    "text": "Epi/Biostatistics\n\nClinical Epidemiology Project: Alzheimer‚Äôs Disease Subgroup Analysis\n Clinical Epidemiology Project: Alzheimer‚Äôs Disease Subgroup Analysis \nAffiliation: Summer Research, Western Michigan University | Jun 2024 ‚Äì Aug 2024\nDataset: ACTC Solanezumab Preclinical Trial Data\nPurpose: To assess subgroup-specific treatment effects and identify cognitive decline risk factors\nMethods:\n- Regression modeling on MMSE and ARIA endpoints\n- Subgroup analyses by APOE4 status, centiloid level, education, and BMI\nResult: Found that surrogate endpoint selection (MMSE vs.¬†ARIA) influences identified risk profiles. APOE4 status and centiloid level showed consistent association with AD progression across subgroups."
  },
  {
    "objectID": "Projects.html#epidemiologybiostatistics",
    "href": "Projects.html#epidemiologybiostatistics",
    "title": "Projects",
    "section": "Epidemiology/Biostatistics",
    "text": "Epidemiology/Biostatistics\n\nClinical Epidemiology Project: Alzheimer‚Äôs Disease Subgroup Analysis\n Clinical Epidemiology Project: Alzheimer‚Äôs Disease Subgroup Analysis \nAffiliation: Summer Research, Western Michigan University | Jun 2024 ‚Äì Aug 2024\nDataset: ACTC Solanezumab Preclinical Trial Data\nPurpose: To assess subgroup-specific treatment effects and identify cognitive decline risk factors\nMethods:\n- Regression modeling on MMSE and ARIA endpoints\n- Subgroup analyses by APOE4 status, centiloid level, education, and BMI\nResult: Found that surrogate endpoint selection (MMSE vs.¬†ARIA) influences identified risk profiles. APOE4 status and centiloid level showed consistent association with AD progression across subgroups."
  },
  {
    "objectID": "Projects.html#methodology-numerical-method-based-estimation",
    "href": "Projects.html#methodology-numerical-method-based-estimation",
    "title": "Projects",
    "section": "Methodology & Numerical Method Based Estimation",
    "text": "Methodology & Numerical Method Based Estimation\n\nRobust Survival Estimation under Interval Censoring: EM Algorithm Assessment via Simulation and Application\n\nRobust Survival Estimation under Interval Censoring: EM Algorithm Assessment via Simulation and Application\nAffiliation: Arnold School of Public Health | Aug 2025 ‚Äì Present\nDataset: Simulated interval-censored survival data (true Weibull baseline) and real-world ovarian cancer dataset with periodic follow-up visits\nObjective: To evaluate the accuracy, predictive performance, and practical utility of the EM algorithm for interval-censored survival analysis, benchmarked against parametric and Bayesian AFT models.\nMethods\n- Turnbull‚Äôs Nonparametric Maximum Likelihood Estimator (NPMLE) via the EM algorithm for distribution-free baseline survival estimation\n- Parametric Weibull AFT models with covariates for individualized prediction\n- Bayesian AFT models for uncertainty quantification and posterior predictive checks\n- Performance evaluation using Integrated Squared Error (ISE) in simulation and Integrated Brier Score (IBS) in real data\nResults\n- EM algorithm: High-fidelity recovery of the true survival curve (ISE = 0.0921; 95% CI: 0.0404‚Äì0.1793) without parametric constraints\n- Weibull AFT: Outperformed Kaplan‚ÄìMeier in predictive accuracy on real data (IBS = 0.064 vs.¬†0.066)\n- Bayesian AFT: Enhanced uncertainty quantification and model selection capabilities\n- Proposed a three-phase modeling workflow: EM for initial shape recovery, AFT for predictive modeling, and Bayesian AFT for robust uncertainty propagation‚Äîvalidated in both simulated and applied settings."
  },
  {
    "objectID": "Projects.html#bayesian-numerical-method-based-estimation",
    "href": "Projects.html#bayesian-numerical-method-based-estimation",
    "title": "Projects",
    "section": "Bayesian & Numerical Method Based Estimation",
    "text": "Bayesian & Numerical Method Based Estimation\n\nRobust Survival Estimation under Interval Censoring: EM Algorithm & Bayesian Assessment via Simulation and Application\n\nRobust Survival Estimation under Interval Censoring: EM Algorithm Assessment via Simulation and Application\nAffiliation: Arnold School of Public Health | Aug 2025 ‚Äì Present\n\nDataset\nSimulated interval-censored survival data (true Weibull baseline) and real-world ovarian cancer dataset with periodic follow-up visits\n\n\nObjective\nTo evaluate the accuracy, predictive performance, and practical utility of the EM algorithm for interval-censored survival analysis, benchmarked against parametric and Bayesian AFT models.\n\n\nMethods\n\nTurnbull‚Äôs Nonparametric Maximum Likelihood Estimator (NPMLE) via the EM algorithm for distribution-free baseline survival estimation\n\nParametric Weibull AFT models with covariates for individualized prediction\n\nBayesian AFT models for uncertainty quantification and posterior predictive checks\n\nPerformance evaluation using Integrated Squared Error (ISE) in simulation and Integrated Brier Score (IBS) in real data\n\n\n\nResults\n\nEM algorithm: High-fidelity recovery of the true survival curve (ISE = 0.0921; 95% CI: 0.0404‚Äì0.1793) without parametric constraints\n\nWeibull AFT: Outperformed Kaplan‚ÄìMeier in predictive accuracy on real data (IBS = 0.064 vs.¬†0.066)\n\nBayesian AFT: Enhanced uncertainty quantification and model selection capabilities\n\nProposed a three-phase modeling workflow: EM for initial shape recovery, AFT for predictive modeling, and Bayesian AFT for robust uncertainty propagation‚Äîvalidated in both simulated and applied settings."
  },
  {
    "objectID": "Projects.html#epidemiology-biostatistics",
    "href": "Projects.html#epidemiology-biostatistics",
    "title": "Projects",
    "section": "Epidemiology & Biostatistics",
    "text": "Epidemiology & Biostatistics\n\nClinical Epidemiology Project: Alzheimer‚Äôs Disease Subgroup Analysis\n Clinical Epidemiology Project: Alzheimer‚Äôs Disease Subgroup Analysis \nAffiliation: Summer Research, Western Michigan University | Jun 2024 ‚Äì Aug 2024\n\nDataset\nACTC Solanezumab Preclinical Trial Data\n\n\nPurpose\nTo assess subgroup-specific treatment effects and identify cognitive decline risk factors\n\n\nMethods\n\nRegression modeling on MMSE and ARIA endpoints\n\nSubgroup analyses by APOE4 status, centiloid level, education, and BMI\n\n\n\nResult\nFound that surrogate endpoint selection (MMSE vs.¬†ARIA) influences identified risk profiles. APOE4 status and centiloid level showed consistent association with AD progression across subgroups."
  },
  {
    "objectID": "Publications.html#preprints",
    "href": "Publications.html#preprints",
    "title": "Publications & Conferences",
    "section": "Preprints",
    "text": "Preprints\n1. Korley, J. T.* (2025). Robust Survival Estimation under Interval Censoring: Expectation-Maximization and Bayesian Accelerated Failure Time Assessment via Simulation and Application. arXiv preprint arXiv:2508.16894.  2. Korley, J. T.* (2025). Individualized Treatment Effects in Advanced Prostate Cancer: A Causal-Survival Modeling Approach to Risk-Guided Therapy. arXiv preprint arXiv:2508.16894.  3. Kubuafor, E., Baidoo, D., Okeke, O. J., Amevor, R., Arhin, G., & Korley, J. T.* (2025). Evaluation of Time Series Forecasting Models for Predicting Lung Cancer Mortality Rates in the United States: A Comparison with Altuhaifa (2023) Study. arXiv preprint arXiv:2508.16052."
  },
  {
    "objectID": "Publications.html#conference-proceedings-poster-presentations",
    "href": "Publications.html#conference-proceedings-poster-presentations",
    "title": "Publications & Conferences",
    "section": "Conference Proceedings: Poster Presentations",
    "text": "Conference Proceedings: Poster Presentations\n1.Sukanya B. , Korley, J. T.*, Peng Y., Wang R.(2025). Dose-Finding and Missing Data Analysis in a Simulated Phase II Psoriasis Trial. Statistics In Pharceutical-UCONN 2025. \n2. Korley, J. T.* (2025). Individualized Treatment Effects in Advanced Prostate Cancer: A Causal-Survival Modeling Approach to Risk-Guided Therapy. Statistics In Pharceutical-UCONN 2025."
  },
  {
    "objectID": "Projects.html#neuroimaging-survival-analysis",
    "href": "Projects.html#neuroimaging-survival-analysis",
    "title": "Projects",
    "section": "NeuroImaging & Survival Analysis",
    "text": "NeuroImaging & Survival Analysis\n\nTiming of First Neuroimaging in Alzheimer‚Äôs Disease: A Competing-Risk Analysis of Genetic, Cognitive, and Demographic Determinants\n\nTiming of First Neuroimaging in Alzheimer‚Äôs Disease: A Competing-Risk Analysis of Genetic, Cognitive, and Demographic Determinants\nAffiliation: Arnold School of Public Health | Oct 2025 ‚Äì Present\n\nDataset\nNational Alzheimer‚Äôs Coordinating Center (NACC) UDS v3 (2015‚Äì2024), linked MRI supplement across 39 Alzheimer‚Äôs Disease Centers\n\n\nObjective\nTo examine how genetic, cognitive, and demographic factors influence when participants receive their first MRI, while appropriately treating death before imaging as a competing event.\n\n\nBackground\nThis work is among the first to model the timing of neuroimaging acquisition rather than outcomes derived from MRI. Because MRI ordering varies across clinical, structural, and demographic factors, understanding these patterns highlights inequities in diagnostic access and the representativeness of imaging research cohorts.\n\n\nMethods\n\nDefined a cause-specific survival process:\n\nEvent 1: first MRI,\n\nEvent 2: death before MRI.\n\n\nModeled event times using parametric AFT models (Weibull for MRI; log-logistic for death).\n\nIncluded APOE Œµ4 genotype, age, sex, race/ethnicity, education, CDR Global, living situation, independence, and B12 deficiency.\n\nConducted sensitivity analyses using cause-specific Cox models with time-varying effects for age, education, and race to address PH violations.\n\nDeveloped an interactive prediction tool:\nShiny App: Time to First MRI Predictor\n\n\n\nResults\n\nAPOE Œµ4 did not influence MRI timing after accounting for demographics and cognition.\n\nOlder age, lower education, and non-White race were strong predictors of delayed MRI.\n\nHigher education and greater independence corresponded to earlier MRI acquisition.\n\nTime-varying analyses showed early, pronounced disparities that attenuate over longer follow-up.\n\n-Presentation SlideASPH,Columbia\n-Extension\nPET-based extension; hierarchical (center-level) AFT models; and Bayesian estimation to capture uncertainty and between-center variability.\nAlso expanding the Shiny app to support clinician-facing and research use."
  },
  {
    "objectID": "Projects.html#methodology-theory-works",
    "href": "Projects.html#methodology-theory-works",
    "title": "Projects",
    "section": "",
    "text": "Covariate-Adjusted Treatment Effects for Recurrent Events with Terminal Outcomes\n\nCovariate-Adjusted Treatment Effects for Recurrent Events with Terminal Outcomes\nAffiliation: Arnold School of Public Health | Oct 2025 ‚Äì Present\nKeywords: Recurrent events; terminal events; causal inference; covariate adjustment; clinical trials; survival analysis\n\nFoundational work:\nSun, J., Ye, T., et al.\nImprove the Precision of Area Under Curve Estimation for Recurrent Events Through Covariate Adjustment\nhttps://arxiv.org/html/2410.24163v3\n\n\n\nTo develop an estimand-driven, covariate-adjusted causal framework for treatment effects on recurrent clinical outcomes when a terminal event (e.g., death) may change survival and, as a consequence, the amount of time recurrent outcomes are observable. \n\n\n\nRecurrent event endpoints are common in clinical trials, including adverse events, hospitalizations, and disease flares. When a terminal event occurs, standard summaries of recurrent outcomes can be difficult to interpret because treatment can affect both (i) the recurrence process and (ii) survival time.\nRecent work by Sun and Ye et al. developed covariate-adjusted inference for an AUC of the mean cumulative function (MCF) estimand. Their estimand can be written (schematically) as an AUC functional of an MCF that depends on both the recurrent event rate and survival. As a result, when treatment affects survival, the estimand can change even if the underlying recurrent event rate does not, complicating scientific interpretation in settings where the goal is to isolate recurrence effects. \n\n\n\nThis project extends the Sun‚ÄìCook line of work by refining the causal estimand and developing an estimator that targets recurrence effects in a way that is orthogonal to survival differences. The goal is an estimand whose treatment contrast is zero when treatment affects survival only (but not recurrence), and nonzero only when treatment changes recurrence dynamics.\nKey contributions: - A survival-orthogonal recurrence-burden estimand that removes survival-weighting from the target, improving interpretability when survival differs by arm. - An orthogonal, influence-function‚Äìbased estimator enabling: - valid covariate-adjusted inference,\n- robustness to nuisance-model misspecification,\n- improved precision under randomized trials. - A causal framing aligned with modern estimand principles for intercurrent events in clinical trials. \n\n\n\nSimulations were conducted under three mechanisms:\n\nNo treatment effect on survival\n\nTreatment benefit on survival\n\nTreatment harm on survival\n\nAcross scenarios, we compared:\n\nthe proposed orthogonal estimator, and\n\nestimators corresponding to standard MCF/AUC-based summaries from prior literature.\n\nPerformance metrics included bias, variance, and power under covariate adjustment. \n\n\n\nLet \\(N_i(t)\\) denote the counting process for recurrent events up to time \\(t\\) for subject \\(i\\), and let \\(D_i\\) denote the terminal event time (e.g., death). Let \\(C_i\\) denote administrative censoring and \\(T_i=\\min(D_i,C_i)\\), with at-risk indicator \\(Y_i(t)=I(T_i\\ge t)\\). Let \\(A_i\\in\\{0,1\\}\\) denote treatment assignment.\nA common summary for recurrent events is the mean cumulative function (MCF): \\[\n\\mu_a(t)=\\mathbb{E}\\{N_i(t)\\mid A_i=a\\},\n\\] which averages recurrent event counts over all individuals. In the presence of a terminal event, MCF-based AUC summaries typically incorporate survival, so treatment effects on survival can influence the estimand even when recurrence dynamics are unchanged.\n\n\nDefine the marginal cumulative recurrence rate (Nelson‚ÄìAalen type target) \\[\nR_a(t)=\\int_0^t \\mathbb{E}\\{\\lambda_a(u\\mid X)\\}\\,du,\n\\] where \\(\\lambda_a(u\\mid X)\\) is the recurrent event intensity among those at risk under treatment \\(a\\).\nWe define the orthogonal recurrence-burden AUC \\[\n\\widetilde U_a(\\tau)=\\int_0^\\tau R_a(t)\\,dt\n=\\int_0^\\tau (\\tau-u)\\,dR_a(u),\n\\] and the treatment contrast \\[\n\\Delta_{\\text{orth}}(\\tau)=\\log\\left\\{\\frac{\\widetilde U_1(\\tau)}{\\widetilde U_0(\\tau)}\\right\\}.\n\\]\nKey property (survival orthogonality): if \\(dR_1(u)=dR_0(u)\\) for all \\(u\\le\\tau\\), then \\(\\widetilde U_1(\\tau)=\\widetilde U_0(\\tau)\\) and \\(\\Delta_{\\text{orth}}(\\tau)=0\\), even when survival differs by arm. This isolates recurrence effects from survival effects and yields a clearer clinical interpretation. \n\n\n\n\n\n\nThe orthogonal estimator closely tracks the true recurrence effect across regimes, while standard AUC-based estimators deviate when survival differs by treatment arm.\n \n##### Bias Induced by Survival Effects\nWhen survival is treatment-dependent, MCF/AUC-based estimators can exhibit systematic bias relative to a pure recurrence target. The orthogonal estimand substantially reduces this bias.\n \n\n\n\nAfter covariate adjustment, the orthogonal estimator maintains competitive or improved power without inflating type I error.\n \n\n\n\n\nThis framework supports clearer interpretation of repeated clinical outcomes in the presence of death or permanent discontinuation, with direct relevance to: - safety endpoints,\n- recurrent hospitalizations,\n- chronic disease flares,\n- oncology and neurodegenerative trials. \n\n\n\n\nMethodological development complete\n\nSimulation study ongoing\n\nManuscript in preparation"
  }
]